ANALYSIS OF HIV PROTECTIVE IMMUNITY

艾滋病疫苗和治疗发展的一个主要障碍是 对什么构成保护性免疫的理解不全面 HIV-1。 我们正在继续研究体液免疫和细胞免疫在 预防艾滋病毒感染，我们正在研究对 感染患者中的艾滋病毒。使用设计的模型病毒培养系统 为了支持主要的艾滋病毒分离株，我们观察到受感染的个人 携带具有不同抗体的准种病毒 中和灵敏度。一般来说，具有嗜性的分离物 巨噬细胞对抗体具有抵抗力，而嗜T细胞分离株表现出 提高了抗体的敏感性。晚期患者有HIV分离株 它们对抗体具有抵抗力，与病毒表型无关。 我们的数据表明，病毒中和和逃避抗体 取决于抗体库、病毒表型和病毒变异。在……里面 去年，我们启动了关于异性恋病毒传播的研究 并正在应用和开发检测其抗病毒活性的方法 阴道产品上的主要病毒。我们还启动了关于 对艾滋病毒的细胞免疫反应，发现患者甚至晚了 在疾病中有能力产生MHC受限的效应细胞 对抗病毒蛋白。

A major obstacle to AIDS vaccine and therapeutic development is the incomplete understanding of what constitutes protective immunity to HIV-1. We are continuing to study the role of humoral and cellular immunity in preventing HIV infection and we are investigating the immune response to HIV in infected patients. Using model viral culture systems designed to support primary HIV isolates, we observe that infected individuals carry a quasispecies of viruses which have different antibody neutralization sensitivities. In general, isolates with tropism for macrophages are antibody resistant, while T cell tropic isolates show increased antibody sensitivity. Late stage patients harbor HIV isolates which are resistant to antibodies, independent of the virus phenotype. Our data demonstrate that virus neutralization and escape from antibodies depends on antibody repertoire, virus phenotype and virus variation. In the last year, we initiated studies on heterosexual virus transmission and are applying and developing assays to measure antiviral activity of vaginal products on primary viruses. We also initiated projects on the cellular immune response to HIV and are finding that patients even late in disease have the ability to generate MHC-restricted effector cells against viral proteins.